Tel aviv listed together pharma's subsidiary globus pharma ltd and bynd cannasoft enterprises' subsidiary sign first commercial agreement for medical cannabis products

Vancouver, british columbia and ashkelon, israel, oct. 27, 2022 (globe newswire) -- bynd cannasoft enterprises inc. (nasdaq: bcan) (cse: bynd) ("bynd cannasoft" or the "company") announced today its israeli subsidiary signed an agreement with globus pharma ltd, a subsidiary of israeli-based together pharma ltd (ta: tgtr), for the cultivation, production, and distribution of medical cannabis products that are expected to generate significant revenues for the company before costs of manufacturing and distribution fees. the manufacturing of the medical cannabis products will adhere to bynd cannasoft's instructions and stringent standards. these products will be exclusively marketed and distributed by bynd cannasoft in israel through globus pharma. due to their safety profile and strong therapeutic efficacy, the products are based on strains developed by together pharma and selected exclusively by bynd cannasoft.
BCAN Ratings Summary
BCAN Quant Ranking